Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development
Coherus Oncology reported interim TREGCHECK data showing tagmokitug plus toripalimab and chemo achieved a 75% confirmed ORR in front-line esophageal squamous cell carcinoma, rising to 89% after the data cutoff, versus a 44-59% standard-of-care benchmark for PD-L1 positive patients. Second-line ESCC showed durable benefit with the 700 mg dose, including 5.5-month median PFS versus a ~3.4-month chemo benchmark, and activity was seen across five indications in over 120 patients with no new safety signals.
Key figures
- Drug Name
- tagmokitug (anti-CCR8 antibody)
- Phase Of Trial
- Phase 1b/2a
- Crc 4l mss cor
- 5.9%
- Irae grade 3 5
- 20%
- Upper gi 700mg cor
- 23.5%
- Irae rate all grades
- 40%
- Second line 700mg cbr
- 33.3% (2/6)
- Second line 700mg cor
- 16.7% (1/6)
- Hnscc hpv positive cor
- 13.0% (3/23)
- Us soc chemo mpfs months
- 3.4
- Patients treated combination
- over 120
- Second line 700mg mpfs months
- 5.5
- First line escc cor all comers
- 75% (6/8)
- First line escc cor post cutoff
- 89% (8/9)
- Hnscc hpv positive tiri plus cbr
- 45% (6/11)
- First line escc cor pd l1 positive
- 100%
- Us soc pd l1 positive cor benchmark
- 44%-59%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.